若生智能
Drug Database
BE

benzydamine flufenamate (Agilona)

✓ Approved

Vinas · PTGS1 · 小分子

什么是 benzydamine flufenamate？

benzydamine flufenamate 是一种小分子，由Vinas研发。该药已获批，用于治疗相关适应症，给药途径：Topical。

药物档案

商品名Agilona
公司Vinas
药物类别小分子
分子靶点PTGS1, PTGS2
给药途径Topical
状态Approved
来源： ClinicalTrials.gov, Vinas

作用机制

分子靶点

benzydamine flufenamate 作用于 2 个分子靶点：

PTGS1prostaglandin-endoperoxide synthase 1 (COX3, PCOX1)
PTGS2prostaglandin-endoperoxide synthase 2 (GRIPGHS, hCox-2)
需要更深入的分析？Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

benzydamine flufenamate 针对 2 个适应症，涉及 2 个治疗领域。

治疗领域疾病/病症分期
Gastrointestinal disordersAbdominal pain✓ Approved
Hepatobiliary disordersHepatitis✓ Approved

相关研究文献

PubMedCancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique2026-08-08

Radiation-induced oral mucositis: Correlation between clinician-assessed WHO grades and patient-reported outcomes, an exploratory prospective observational pilot study.

Kumar Priya P, Singh Kuldeep K, Augustine Jeyaseelan J, Urs Aadithya B AB

Oral mucositis is a frequent, dose-limiting toxicity of chemoradiotherapy of head and neck cancer. Clinician-based grading such as the world health organization mucositis scale provides objective assessment of visible lesions, but patient-reported oral mucositis symptom scale capture the subjective functional impact, which may not always correspond with clinical findings. This pilot study examined the association between clinician grading and patient-reported measures and explored differences between benzydamine and bicarbonate rinses. Twenty patients with head and neck cancer receiving definitive chemoradiotherapy were enrolled; ten received benzydamine and ten bicarbonate rinses. Weekly world health organization mucositis grading and patient-reported oral mucositis symptoms (10-item Visual Analogue Scale assessing pain, speech, eating, swallowing, and taste) were recorded across seven weeks. Spearman's correlation was performed, and descriptive comparisons were made between rinse groups. All patients developed mucositis by week 7. Peak severity ranged from grade 1 to grade 4, with most patients reaching grade 3. Median onset of ulcerative mucositis (grade 2 or worse) was week 3. Patient-reported oral mucositis symptoms correlated with World Health Organization grades (Spearman's ρ=0.72, p<0.01) and increased with ulcerative progression. Taste alteration and difficulty eating solids were most affected domains. Some patients reported symptoms despite absent visible lesions. No significant differences were found between the two rinse groups. Patient-reported outcome measure symptoms scale strongly complement World Health Organization grading, capturing symptom escalation and functional impairments under-recognized by clinician assessment. Findings support the need for larger multicentre studies integrating clinician and patient assessments.

PMID 42566859
阅读全文 →
PubMedPolymers2026-07-28

Supercritical CO2-Assisted Impregnation of Absorbable Surgical Sutures with Carvacrol and Benzydamine Hydrochloride: Comparative In Vitro Release Profiles and Drug Release Kinetics.

Akpınar Aysun A, Öztürk Merve M, Aybastıer Önder Ö, Çelik Halil H et al.

The development of bioactive surgical sutures capable of delivering therapeutic agents directly at the wound site has gained increasing attention in biomedical research. Functionalized sutures may provide localized antimicrobial or anti-inflammatory activity, potentially reducing postoperative complications and promoting tissue healing. In this study, absorbable surgical sutures were impregnated with carvacrol, a natural phenolic compound with well-known antimicrobial properties, using supercritical carbon dioxide (scCO2) technology. The impregnation process was carried out at 35 °C and 10 MPa for 120 min, allowing for the incorporation of carvacrol into the polymeric matrix of the sutures. The in vitro release behavior of the impregnated sutures was evaluated in phosphate-buffered saline (PBS, pH 7.4) at 37 °C over an 8-day period. The concentration of released compounds was determined by UV-Vis spectrophotometry using previously established calibration curves. An analysis of the experimental release data demonstrated that both carvacrol and benzydamine hydrochloride (HCl) (Tantum Verde®) exhibited a sustained release profile throughout the incubation period. Carvacrol release increased progressively from 2.02 ± 0.15 ppm on day 1 to 7.45 ± 0.15 ppm on day 7, followed by a slight stabilization on day 8 (7.25 ± 0.31 ppm). Similarly, benzydamine HCl (Tantum Verde®) release increased from 1.83 ± 0.11 ppm on day 1 to 3.29 ± 0.13 ppm on day 8. Release kinetics were analyzed using the Korsmeyer-Peppas model, indicating that the release mechanism was predominantly diffusion-controlled during the initial stage of the experiment. The results demonstrate that supercritical CO2 impregnation is an effective solvent-free technique for incorporating bioactive compounds into absorbable sutures, enabling controlled release under physiological conditions.

PMID 42514751
阅读全文 →
PubMedPharmaceuticals (Basel, Switzerland)2026-07-28

Effect of Benzydamine Hydrochloride on Dental Plaque Accumulation During Short-Term Restricted Oral Hygiene: A Randomized, Placebo-Controlled Trial.

Puhar Ivan I, Paleško Tubikanec Tina T, Glavina Sabina S, Borovac Matija M et al.

Background/Objectives: Benzydamine hydrochloride (B-HCl) is a non-steroidal anti-inflammatory agent with antimicrobial properties that may be beneficial in oral biofilm control. The aim of this study was to evaluate the effect of a 0.15% B-HCl mouthrinse on dental plaque accumulation and gingival inflammation under short-term conditions of restricted mechanical oral hygiene. Methods: Fifty periodontally healthy female subjects (aged 16-27 years) were randomly assigned (1:1) to receive either a 0.15% B-HCl mouthrinse or a placebo. Following professional prophylaxis, subjects rinsed with 15 mL twice daily for 30 s and refrained from all other oral hygiene procedures for 3 days. Full-Mouth Plaque Score (FMPS) was the primary outcome, and Full-Mouth Bleeding Score (FMBS) was the secondary outcome, recorded at baseline (Day 0) and Day 3. This study was conducted in accordance with CONSORT guidelines. Results: All subjects (n = 50) completed the study. FMPS increased significantly in both groups (p < 0.001). However, plaque accumulation at Day 3 was significantly lower in the B-HCl group compared with placebo (47.9% vs. 73.8%, p < 0.001), representing an absolute reduction of 25.9% and a relative reduction of 35.1%. No statistically significant differences were observed between groups in FMBS at Day 3 (p = 0.180). Conclusions: A 0.15% B-HCl mouthrinse reduced dental plaque accumulation compared with placebo during a 3-day period of restricted mechanical oral hygiene (mean difference: 25.9%; 95% CI: 16.1% to 35.7%). Given the short study duration, the anti-inflammatory properties of B-HCl could not be adequately evaluated. Longer-term studies are needed to determine whether B-HCl provides clinically meaningful benefits as an adjunct to mechanical oral hygiene. Trial registration: ClinicalTrials.gov (Identifier: NCT07565766).

PMID 42515697
阅读全文 →
PubMedRSC advances2026-05-13

Eco-friendly differential pulse voltammetric determination of benzydamine hydrochloride using a gold nanoparticles-modified carbon paste electrode.

Bakr Maryam A MA, Abbas Samah S SS, Hegazy Maha A MA, Badawey Amr M AM et al.

A differential pulse voltammetric (DPV) method is presented for the determination of benzydamine hydrochloride (BZ) in bulk powder, mouthwash, and artificial saliva matrices. This work represents the first application of DPV for the electrochemical determination of BZ. The method employs a carbon paste electrode (CPE) modified with electrodeposited gold nanoparticles (Au-NPs) through a chronoamperometric step, which significantly enhances the oxidation peak current for BZ within the potential window of 0.0 to 1.6 V. The variables, most significantly the pH and scan rate, affecting the voltammetric response were systematically optimized. Under the optimized conditions, the proposed sensor exhibited a linear response over the concentration range of 1.00-10.00 µM with a limit of detection (LOD) of 0.1024 µM. Validation in accordance with the ICH guidelines confirmed satisfactory accuracy and precision. The applicability of the developed method was further verified through the successful quantification of BZ in mouthwash formulations and artificial saliva samples. The proposed DPV approach provides a complementary analytical alternative rather than a replacement, which was evidenced by comparison with the reported electrochemical methods. In addition, the environmental and practical performance of the method was assessed using established greenness and applicability metrics, confirming that the proposed approach combines analytical effectiveness with a low environmental burden and favorable practical characteristics.

PMID 42124840
阅读全文 →
PubMedACS omega2026-04-27

Synthesis and Structure Elucidation of New NSAID Diphosphine Ruthenium(II) Complexes as Potential Anticancer Agents: DNA/BSA Binding and Cytotoxicity Assays.

Carvalho Diogo E L DEL, Teixeira Tamara T, de Araujo-Neto João Honorato JH, Batista Alzir A AA et al.

New diphosphine ruthenium-(II) complexes with nonsteroidal anti-inflammatory drugs (NSAID) derivatives with general formula [Ru-(L)-(dppe)2]-PF6 [dppe = 1,2-bis(diphenylphosphine)-ethane and (L) corresponds to fenamate (fe-) (Complex 1), mefenamate (me-) (Complex 2), tolfenamate (tol-) (Complex 3) or flufenamate (flu-) (Complex 4)] were synthesized. All compounds were characterized by several techniques, including 1H, 13C-{1H} and 31P-{1H} NMR, cyclic voltammetry, conductivity, elemental analysis, ultraviolet/visible absorption spectroscopy, infrared absorption spectroscopy and single crystal X-ray diffraction. ct-DNA (Calf-Thymus DNA) interaction studies by spectroscopic titrations and viscosity measurements demonstrated that the complexes may interact weakly with ct-DNA, considering that the complexes are cationic and that DNA carries a negative charge due to its phosphate groups, electrostatic interactions could occur. The complexes showed a moderate interaction with Bovine Serum Albumin (BSA) mediated by both dynamic and static quenching mechanisms. Also, the cytotoxic activity of the complexes was evaluated against breast (MDA-MB-231) and lung (A549) tumor cell lines and nontumor lung (MRC-5) cell lines. All complexes showed cytotoxicity against the cell lines investigated, with IC50 values in the range of 0.94-17.71 μM. [Ru-(me)-(dppe)2]-PF6 showed a high selectivity index against the A549 cell line. For MDA-MB-231 cell line, the most selective complex was [Ru-(fe)-(dppe)2]-PF6. Except for [Ru-(tol)-(dppe)2]-PF6, all other complexes were more cytotoxic than cisplatin, making them promising compounds.

PMID 42040486
阅读全文 →
PubMedInternational journal of biological macromolecules2026-04-25

Direct powder extrusion 3D printing of a polyhydroxybutyrate-based dual-release drug delivery device for dental therapy.

Fratini Costanza C, Grandoni Matteo M, Vanzolini Tania T, Aluigi Annalisa A et al.

This study investigates the processability of polyhydroxybutyrate (PHB) in different physical forms (i.e., powder, pellets, and granules) using direct powder extrusion (DPE) 3D printing (3DP), a technique that enables the direct use of raw materials without prior filament fabrication. The raw materials were thoroughly characterized with respect to their thermal properties to evaluate their suitability for additive manufacturing application. Two DPE 3D printers employing distinct extrusion-driven mechanisms were used to enable a comparative evaluation under identical material conditions. Following printing, the resulting scaffolds were assessed in terms of their thermal, chemical and morphological characteristics to determine the feasibility and performance of each material form within the DPE 3D-printing process. In the second phase of the work, the potential of DPE to fabricate a functional PHB-based dental device enabling dual drug release (i.e., immediate and extended) was investigated. This was achieved by optimizing the printed geometry to incorporate a hydrophilic gel reservoir for burst release. Benzydamine hydrochloride, a non-steroidal anti-inflammatory drug with anti-inflammatory and antimicrobial properties, was selected as the model drug due to its compatibility with PHB processing temperatures (∼160 °C). The drug-loaded devices were successfully printed and evaluated through in vitro release studies and antimicrobial testing, confirming both controlled release and biological activity. The findings support the use of PHB and DPE 3DP for the development of customizable, biodegradable drug delivery systems, with promising applications in oral and dental care.

PMID 42031248
阅读全文 →

注册免费账户还可查看另外 758 篇文献

免费注册查看全部文献 →

了解更多benzydamine flufenamate